(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Administration’s Executive Order to resurrect the rebate rule. “The Administration’s decision last year to withdraw a proposed regulation on prescription drug
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the U.S. House of Representatives’ vote on prescription drug price transparency legislation: “PBMs support increasing transparency across the entire prescription drug supply
See Infographic on prescription drug price increases in Medicare Part B
Three U.S. senators are seeking more information from a Florida company that has steadily increased the price of a 40-year-old cancer drug
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s February 24, 2021, Executive Order on America’s Supply Chains. “As representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter
President Donald Trump is trying to shame the largest U.S. drugmaker for hiking prices after he earlier said industry players were planning “massive” price reductions.
“We support (the administration’s) call for greater flexibility in benefit design to encourage better price negotiations…” PCMA said
Sanofi and Regeneron have agreed to lower the price of their cholesterol medicine in exchange for easier access for patients covered by pharmacy benefit manager
Increasing list prices are not correlated with changes in prescription drug rebates.
©2024 PCMA. All Rights Reserved.
